Human Anti-Cytokeratin 7 Antibody Product Attributes
Cytokeratin 7 Previously Observed Antibody Staining Patterns
Observed Antibody Staining Data By Tissue Type:
Variations in Cytokeratin 7 antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in glandular cells in the breast, cervix, uterine, endometrium, fallopian tube, gallbladder, salivary gland, seminal vesicle and thyroid gland, respiratory epithelial cells in the bronchus and nasopharynx, trophoblastic cells in the placenta and urothelial cells in the urinary bladder. More moderate antibody staining intensity was present in glandular cells in the breast, cervix, uterine, endometrium, fallopian tube, gallbladder, salivary gland, seminal vesicle and thyroid gland, respiratory epithelial cells in the bronchus and nasopharynx, trophoblastic cells in the placenta and urothelial cells in the urinary bladder. Low, but measureable presence of Cytokeratin 7 could be seen inglandular cells in the parathyroid gland and stomach and myoepithelial cells in the breast. We were unable to detect Cytokeratin 7 in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of Cytokeratin 7 expression as measured by anti-Cytokeratin 7 antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | +++ | – | +++ | – | ++ | – | – | + | +++ | – | – | +++ | +++ | + | – | – | +++ | – | +++ | +++ |
| KRT7 Variability | ++ | + | ++ | + | ++ | + | + | ++ | + | + | + | + | + | +++ | + | ++ | ++ | + | + | + |
| Cytokeratin 7 General Information | |
|---|---|
| Alternate Names | |
| Keratin, type II cytoskeletal 7, cytokeratin-7, CK-7, keratin-7, K7, sarcolectin, SCL, KRT7 | |
| Molecular Weight | |
| 55kDa | |
| Chromosomal Location | |
| 12q13.13 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | KRT7 |
| Entrez Gene ID | 3855 |
| Ensemble Gene ID | ENSG00000135480 |
| RefSeq Protein Accession(s) | NP_005547, XP_016874783, XP_011536627 |
| RefSeq mRNA Accession(s) | XR_001748699, NM_005556, XR_001748700, XM_017019294 |
| RefSeq Genomic Accession(s) | NC_000012, NG_012296, NC_018923 |
| UniProt ID(s) | P08729 |
| UniGene ID(s) | P08729 |
| HGNC ID(s) | 6445 |
| Cosmic ID(s) | KRT7 |
| KEGG Gene ID(s) | hsa:3855 |
| PharmGKB ID(s) | PA30233 |
| General Description of Cytokeratin 7. | |
| It recognizes an intermediate filament protein (IFP) of 55kDa, which is identified as cytokeratin 7. This MAb is highly specific to cytokeratin 7, shows no cross-reaction with other IFPs. Cytokeratin 7 is a basic cytokeratin, which is found in most glandular, transitional epithelia but not in the stratified squamous epithelia. Keratin 7 is expressed in the epithelial cells of ovary, lung,, breast but not of colon, prostate, or gastrointestinal tract. This MAb is highly useful in distinguishing ovarian carcinomas (keratin 7+) from colon carcinomas (keratin 7-). | |
![Analysis of Mass Spec data (dashed-line) of fractions stained with Cytokeratin 7 MS-QAVA™ monoclonal antibody [Clone: KRT7/760 + KRT7/903] (solid-line), reveals that less than 0.3% of signal is attributable to non-specific binding of anti-Cytokeratin 7 [Clone KRT7/760 + KRT7/903] to targets other than KRT7 protein. Even frequently cited antibodies have much greater non-specific interactions, averaging over 30%. Data in image is from analysis in Jurkat, U202 and HeLa cells.](https://cdn-enquirebio.pressidium.com/wp-content/uploads/2017/10/enQuire-Bio-3855-MSM5-P1-anti-Cytokeratin-7-antibody-178x178.png)
![Analysis of Mass Spec data (dashed-line) of fractions stained with Cytokeratin 7 MS-QAVA™ monoclonal antibody [Clone: KRT7/1499R] (solid-line), reveals that less than 13.6% of signal is attributable to non-specific binding of anti-Cytokeratin 7 [Clone KRT7/1499R] to targets other than KRT7 protein. Even frequently cited antibodies have much greater non-specific interactions, averaging over 30%. Data in image is from analysis in A431, RT4 and MCF7 cells.](https://cdn-enquirebio.pressidium.com/wp-content/uploads/2017/10/enQuire-Bio-3855-RBM9-P0-anti-Cytokeratin-7-antibody-178x178.png)
![Analysis of Mass Spec data (dashed-line) of fractions stained with Cytokeratin 7 MS-QAVA™ monoclonal antibody [Clone: KRT7/903] (solid-line), reveals that less than 7.5% of signal is attributable to non-specific binding of anti-Cytokeratin 7 [Clone KRT7/903] to targets other than KRT7 protein. Even frequently cited antibodies have much greater non-specific interactions, averaging over 30%. Data in image is from analysis in A431, RT4 and MCF7 cells.](https://cdn-enquirebio.pressidium.com/wp-content/uploads/2017/10/enQuire-Bio-3855-MSM3-P1-anti-Cytokeratin-7-antibody-178x178.png)
There are no reviews yet.